头孢三唑

IC50: 2.1 μM (α-Glucosidase)
Ki: 0.578 μM (α-Glucosidase)

In in vitro α-Glucosidase assays, Ceftezole is shown to be a reversible, non-competitive inhibitor of yeast α-glucosidase with a K _i value of 5.78×10 ^-7 M when the enzyme mixture is pretreated with ceftezole.

Using an in vivo streptozotocin-induced mouse model, blood glucose levels are confirmed to be decreased by 30% 20 min after Ceftezole treatment (10 mg/kg/day). Expression levels of glycogen synthase kinase-3, peroxisome proliferator-activated receptor-γ, and uncoupling protein-3 mRNA are also slightly decreased compare to controls following Ceftezole treatment.